10x Genomics, Inc.

Annual Trend FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 TTM
Revenue $71.1m
$146.3m +105.83%
$245.9m +68.06%
$298.8m +21.53%
$490.5m +64.13%
$516.4m +5.28%
$618.7m +19.81%
$610.8m -1.28%
$642.8m +5.25%
$616.9m -4.03%
Cost of products and services revenue $10.6m
$28.7m +171.41%
$61.0m +112.95%
$58.5m -4.20%
$74.1m +26.72%
$120.4m +62.48%
$209.4m +73.95%
$196.3m -6.26%
$198.9m +1.34%
Gross profit $60.5m
$117.7m +94.39%
$184.9m +57.12%
$240.4m +30.03%
$416.4m +73.23%
$396.0m -4.89%
$409.3m +3.36%
$414.5m +1.26%
$443.9m +7.09%
$432.0m -2.67%
Research and development $32.2m $47.5m $83.1m $123.4m $211.8m $265.7m $270.3m $264.7m $238.6m $226.8m
In-process research and development $62.4m $0 $447.5m $0 $0 $61.0m $0 $0
Selling, general and administrative $46.7m $87.9m $130.8m $202.3m $257.6m $298.3m $343.3m $344.3m $316.1m $297.0m
Total operating expenses $78.9m $228.4m $215.4m $774.5m $468.7m $564.0m $674.6m $609.0m $504.9m $523.8m
Loss from operations ($18.4m)
($110.8m) -502.80%
($30.6m) +72.40%
($534.1m) -1647.10%
($52.3m) +90.22%
($167.9m) -221.41%
($265.3m) -57.99%
($194.6m) +26.67%
($61.0m) +68.65%
Interest expense ($811k) ($2.4m) ($3.1m) ($1.7m) ($866k) ($476k) ($33k) ($4k) $0 ($3k)
Interest income $308k $1.0m $2.8m $1.5m $206k $6.6m $16.9m $18.4m $20.0m $21.9m
Other income (expense), net $137k ($249k) ($186k) $1.3m ($802k) ($198k) ($307k) ($1.6m) $1.0m ($5.0m)
Total other income ($366k) ($1.6m) ($460k) ($334k) ($1.5m) $6.0m $16.6m $16.9m $21.1m
Loss before provision for income taxes ($18.7m) ($112.4m) ($31.0m) ($534.5m) ($53.7m) ($162.0m) ($248.8m) ($177.7m) ($39.9m)
Provision for income taxes $21k $87k $218k $8.3m $4.5m $4.0m $6.3m $4.9m $3.6m
Net loss ($18.8m) ($112.5m) ($31.3m) ($542.7m) ($58.2m) ($166.0m) ($255.1m) ($182.6m) ($43.5m)
Net loss per share, basic (in dollars per share) ($1) ($5) ($1) ($1) ($2) ($2) ($0)
Net loss per share, diluted (in dollars per share) ($1) ($5) ($1) ($1) ($2) ($2) ($0)
Weighted-average shares used to compute net loss per share, basic (in shares) ($1) ($5) ($1) ($1) ($2) ($2) ($0)
Weighted-average shares used to compute net loss per share, diluted (in shares) ($1) ($5) ($1) ($1) ($2) ($2) ($0)
Gain on settlement $0 $0 ($49.9m)